Europe Blood Glucose Monitoring Market Size

Europe Blood Glucose Monitoring Market Analysis

The Europe Blood Glucose Monitoring Market size is estimated at USD 5.18 billion in 2024, and is expected to reach USD 7.75 billion by 2029, growing at a CAGR of 8.38% during the forecast period (2024-2029).

The COVID-19 pandemic has substantially impacted the blood glucose monitoring market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes have a weak immune system, so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances of serious complications than normal people.

According to the diabetes category, the estimated cost per hospital admission during the first wave of COVID-19 in Europe ranged from EUR 25,018 for type 2 diabetes patients in good glycaemic control to EUR 57,244 for type 1 diabetes patients in poor glycaemic control, reflecting a higher risk of intensive care, ventilator support, and a longer hospital stay. The estimated cost for patients without diabetes was EUR 16,993. The expected total direct expenditures for COVID-19 secondary care in Europe were 13.9 billion euros. Diabetes treatment thus accounted for 23.5% of total expenditures.

The European countries are suffering from the burden of high diabetes expenditure. According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. According to other statistics from IDF, every year, 21,600 children are added to the type-1 diabetic population pool. These figures indicate that approximately 9% of the total healthcare expenditure is spent on diabetes in Europe. 

With the advancements in technology, blood glucose meters have evolved to include cellular-connected devices. These devices automatically upload self-monitoring blood glucose (SMBG) data to secure cloud-based databases. This allows for improved sharing and monitoring of SMBG data. Real-time monitoring of SMBG data presents opportunities to provide timely support to patients who have abnormal SMBG recordings.

Diabetes remote monitoring programs that utilize these technological advancements can offer additional support to patients with poorly controlled diabetes. This support can significantly improve critical outcomes and enhance market prospects in the future.

For patients relying on insulin pumps or multiple daily injections (MDI) therapy, the CGMs are an effective tool that helps improve glycemic balance without aggregating the danger of severe hypoglycemia.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.